Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 0.63 |
| ▸ | THRA | P10827 | 6/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20060965 | 0.88 | THRB (0.50) | THRBTHRAHTTKDM4EALDH1A1 | |
| SCHEMBL22310588 | 0.88 | THRA (0.49) | THRBTHRAHTTKDM4EALDH1A1 | |
| SCHEMBL1750089 | 0.83 | THRB (0.60) | THRBTHRAHTTRECQL | |
| SCHEMBL8876412 | 0.83 | THRB (0.60) | THRBTHRAHTTRECQLKDM4E | |
| SCHEMBL20060900 | 0.82 | THRB (0.46) | THRBTHRAHTTRECQLALDH1A1 | |
| SCHEMBL20061075 | 0.81 | THRB (0.47) | THRBTHRAHTTRECQLALDH1A1 | |
| SCHEMBL6305959 | 0.81 | THRB (0.57) | THRBTHRAHTTRECQLALDH1A1 | |
| SCHEMBL3417202 | 0.81 | THRB (0.64) | THRBTHRA | |
| SCHEMBL29492898 | 0.81 | THRB (0.64) | THRBTHRA | |
| SCHEMBL27389920 | 0.81 | THRB (0.64) | THRBTHRAHTTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | THRB 192/4885THRA 238/4885HTT 1612/4885 |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | THRB 192/4885THRA 238/4885HTT 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.